Recent Investment Analysts’ Ratings Changes for Eton Pharmaceuticals (ETON)

A number of research firms have changed their ratings and price targets for Eton Pharmaceuticals (NASDAQ: ETON):

• 1/10/2025 – Eton Pharmaceuticals is now covered by analysts at B. Riley. They set a “buy” rating and a $21.00 price target on the stock.
• 1/9/2025 – Eton Pharmaceuticals was upgraded by analysts at B. Riley to a “strong-buy” rating.
• 1/8/2025 – Eton Pharmaceuticals had its price target raised by analysts at Craig Hallum from $15.00 to $18.00. They now have a “buy” rating on the stock.
• 1/6/2025 – Eton Pharmaceuticals had its price target raised by analysts at HC Wainwright from $15.00 to $17.00. They now have a “buy” rating on the stock.
• 11/26/2024 – Eton Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock, up previously from $11.00.

Eton Pharmaceuticals Stock Down 0.6 %

ETON traded down $0.08 on Thursday, reaching $14.22. 20,878 shares of the company traded hands, compared to its average volume of 306,409. Eton Pharmaceuticals, Inc. has a one year low of $3.03 and a one year high of $15.00. The firm has a fifty day simple moving average of $12.07 and a two-hundred day simple moving average of $7.67. The company has a market cap of $370.43 million, a P/E ratio of -64.64 and a beta of 1.38.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Westside Investment Management Inc. increased its position in Eton Pharmaceuticals by 5.7% during the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after purchasing an additional 33,275 shares during the period. Geode Capital Management LLC grew its position in shares of Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after buying an additional 32,365 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth approximately $90,000. Parkman Healthcare Partners LLC grew its position in shares of Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after buying an additional 7,029 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth approximately $54,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.